FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. PMID 36809046 · J Clin Oncol · 2023-Aug-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Intraoperative Adverse Events, Technical Performance, and Surgical Outcomes in Laparoscopic Radical Surgery for Gastric Cancer: A Pooled Analysis From 2 Randomized Trials. PMID 36250322 · Ann Surg · 2023-Aug-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A SEER data-based nomogram for the prognostic analysis of survival of patients with Kaposi's sarcoma. PMID 37675717 · J Cancer Res Ther · 2023-Aug The record describes a retrospective prognostic nomogram study using a public database (SEER). It is not a randomized controlled trial of a drug intervention. While it involves an oncologic, human, time-to-event endpoint (cancer-specific survival), it lacks the required elements of a randomized trial of a drug-containing intervention. The 'Randomized Controlled Trial' publication type appears to be a misclassification by the source database, as the methodology describes only a retrospective cohort split for model validation, not a comparative trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [Weidiao-3 Mixture Improves the Clinical Efficacy of Immunotherapy for Advanced Gastric Cancer by Regulating Intestinal Flora]. PMID 37654138 · Zhongguo Yi Xue Ke Xue Yuan Xue Bao · 2023-Aug While the study meets criteria for being a randomized, human oncology trial with a drug intervention and time-to-event primary endpoints, the explicit trial phase (Phase III/IIIb or Phase II/III) is not established in the provided record. Without confirmation of the phase, eligibility cannot be confirmed. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial. PMID 37641544 · Cancer Med · 2023-Aug Record meets all eligibility criteria: it is an original report of a human oncology Phase III randomized controlled trial with a drug-containing intervention and a primary time-to-event efficacy endpoint (overall survival). |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 4 Panel · risk visible |
| [Radiotherapy]. PMID 37608405 · Gan To Kagaku Ryoho · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. PMID 37593752 · Cancer Res Commun · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer. PMID 37575280 · Cancer Res Commun · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Factors Associated With Altmetric Attention Scores for Randomized Phase III Cancer Clinical Trials. PMID 37552823 · JCO Clin Cancer Inform · 2023-Aug The record is a bibliometric analysis of multiple cancer clinical trials, not an original formal-result report of a specific randomized trial with a drug intervention and a primary time-to-event endpoint. It does not meet the core eligibility criteria. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [First-line maintenance therapy of adult patients with BCG-naïve high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) - SunRISe-3 - AB 85/23 of AUO]. PMID 37541235 · Aktuelle Urol · 2023-Aug 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
B
|
旧查询独有 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma. PMID 37489066 · Cancer Med · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term survival in older patients given propofol or sevoflurane anaesthesia for major cancer surgery: follow-up of a multicentre randomised trial. PMID 37474242 · Br J Anaesth · 2023-Aug The study is a randomized trial of anesthetic agents in cancer surgery patients with a survival endpoint, but it does not meet the core requirement of a drug-containing oncology intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. PMID 37457332 · Lancet Reg Health Eur · 2023-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Assessing the reporting quality of adult neuro-oncology protocols, abstracts, and trials: Adherence to the SPIRIT and CONSORT statements. PMID 37457230 · Neurooncol Pract · 2023-Aug The record is a methodological review of reporting quality in neuro-oncology trials, not an original report of a randomized trial's efficacy results. It does not present a drug intervention or time-to-event endpoint from a specific trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212). PMID 37441876 · ESMO Open · 2023-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. PMID 37429302 · Lancet Oncol · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Development and Validation of a Nomogram for Predicting Cancer-Specific Survival and a Risk Stratification System for Patients with Primary Gastrointestinal Melanoma. PMID 37427883 · Turk J Gastroenterol · 2023-Aug The record describes a retrospective, observational study developing a prognostic nomogram from the SEER database. It is not a randomized controlled trial, does not involve a drug intervention, and is not a Phase III or definitive trial report. The publication_type includes 'Randomized Controlled Trial' but this is incorrect per the abstract content. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial. PMID 37423227 · Lancet Oncol · 2023-Aug The study is a phase 3 randomized oncology trial with a primary result, but the intervention is a radiotherapy technique (DO-IMRT vs standard IMRT) without a drug-containing arm, and the primary endpoint is a patient-reported swallowing function score (MDADI), not a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| VEGFR2 and CD34 expression associated with longer survival in patients with pleural mesothelioma in the IFCT-GFPC-0701 MAPS phase 3 trial. PMID 37393757 · Lung Cancer · 2023-Aug The record describes a biomarker analysis (VEGFR2 and CD34) conducted on samples from a larger Phase III trial (MAPS). While the parent trial is eligible (Phase III, randomized, drug-containing, time-to-event endpoints), this specific publication is a secondary/subgroup analysis focused on prognostic and predictive biomarkers, not the primary formal report of the trial's efficacy results. Therefore, it does not meet the 'original_result' criterion for a Kaplan-Meier digitization cohort focused on primary trial outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| 10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection. PMID 37393644 · Breast · 2023-Aug The record describes a randomized trial comparing surgical management strategies (SNBM vs. ALND) for early breast cancer, not a drug-containing intervention. While it is an oncology RCT with time-to-event endpoints, it fails the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16). PMID 37357593 · Br J Haematol · 2023-Aug The study is a phase IIb randomized trial (publication type says Phase III but abstract describes phase IIb) with a drug intervention and original results. However, it is not clearly randomized as described in the abstract, and critically, no time-to-event efficacy endpoint (e.g., OS, PFS) or associated Kaplan-Meier/HR analysis is reported. The primary efficacy outcome is overall response rate (ORR), which is not a time-to-event endpoint. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study). PMID 37348348 · ESMO Open · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Two-stage multivariate Mendelian randomization on multiple outcomes with mixed distributions. PMID 37338962 · Stat Methods Med Res · 2023-Aug The record is a methodological paper that uses a Phase III oncology trial as an application example, not an original report of the trial's efficacy results. It lacks a drug intervention specification and does not present a primary time-to-event endpoint analysis of the trial. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients. PMID 37336651 · Clin Breast Cancer · 2023-Aug The record is from a phase III randomized trial with drug intervention, but it reports a secondary analysis of a biomarker (CTCs) association with obesity, not a primary or key secondary time-to-event efficacy endpoint. Therefore, it does not meet the eligibility criteria for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical and metabolomic characterization of Brivanib-Induced hypertension in metastatic colorectal cancer. PMID 37329221 · Cancer Med · 2023-Aug The record describes a secondary/exploratory analysis of a randomized trial, but does not establish the trial's phase (III/IIIb or II/III) nor is it the primary efficacy result report of the main trial's primary endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study. PMID 37322274 · Rheumatol Ther · 2023-Aug 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Response to letter entitled: Re: Oral cavity adjuvant therapy (OCAT) - a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity. PMID 37321931 · Eur J Cancer · 2023-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Letter Re: Oral cavity adjuvant therapy-a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity. PMID 37321930 · Eur J Cancer · 2023-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Transconjunctival excision of external angular dermoid cyst: A novel approach. PMID 37315491 · J Plast Reconstr Aesthet Surg · 2023-Aug The study is a randomized surgical trial for a benign dermoid cyst, not a malignant neoplasm, lacks a drug intervention, and does not report a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312). PMID 37307753 · Lung Cancer · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy. PMID 37290796 · J Nucl Med · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study. PMID 37277262 · Eur J Cancer · 2023-Aug The record is a meta-research study (a methodological analysis of multiple trials), not an original clinical trial report. It does not meet the core criteria of being an original report of a randomized trial with a drug intervention and a time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Multi-task banded regression model: A novel individual survival analysis model for breast cancer. PMID 37271111 · Comput Biol Med · 2023-Aug The record is an original research article proposing a novel statistical model for survival analysis, not a report of a clinical trial with a drug intervention. Although the abstract mentions a 'randomized clinical trial' (the GBSG dataset), the article itself is a methodological study using published datasets, not the original trial report. There is no drug intervention reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phase II randomised, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198). PMID 37268519 · Eur J Cancer · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effects of Postoperative Intravenous Cyclosporine Treatment on the Survival and Functional Performance Status of Patients With Glioblastoma: A Randomized, Triple-Blinded, Placebo-Controlled Clinical Trial. PMID 37268192 · World Neurosurg · 2023-Aug The study is a randomized, placebo-controlled trial in oncology with drug intervention and time-to-event endpoints, but the formal trial phase (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata or abstract. The deterministic review signal flagged phase evidence as unclear. Eligibility requires explicit confirmation of Phase III/IIIb or Phase II/III status. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. PMID 37247942 · Ann Rheum Dis · 2023-Aug The record is a network meta-analysis evaluating the safety (malignancy risk) of JAK inhibitors across multiple non-oncology inflammatory diseases. It does not meet the inclusion criteria for an original formal-result report of a Phase III/IIIb or Phase II/III randomized trial in human malignant neoplasms with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy. PMID 37246086 · Hematol Oncol Clin North Am · 2023-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study. PMID 37219378 · Clin Pharmacol Ther · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Radiotherapy for Ledderhose disease: Results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial. PMID 37211283 · Radiother Oncol · 2023-Aug The study is a randomised phase 3 trial with primary results, but it is not oncology (treats non-malignant Ledderhose disease), uses a non-drug intervention (radiotherapy), and lacks a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. PMID 37211045 · Ann Oncol · 2023-Aug The record describes the final OS results of the PAOLA-1/ENGOT-ov25 trial, a randomized, placebo-controlled Phase III trial of olaparib plus bevacizumab vs bevacizumab alone in advanced ovarian cancer. It includes a drug-containing intervention, reports key time-to-event efficacy endpoints (OS, PFS), and is an original formal result report. The deterministic review's phase3 evidence concern is resolved by the trial identifier (ENGOT-ov25) and context, which are standard for Phase III oncology trials. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Prognostic impact of tumor size on patients with metastatic colorectal cancer: a large SEER-based retrospective cohort study. PMID 37202599 · Updates Surg · 2023-Aug The study is a retrospective cohort analysis using registry data, not a prospective Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention. While it includes OS as a time-to-event endpoint, it lacks the required drug intervention and trial design. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial. PMID 37201751 · Ann Oncol · 2023-Aug The record describes an original, randomized Phase IV trial with a drug intervention and time-to-event endpoints (primary QoL, secondary PFS/OS). However, it is ineligible because the trial is explicitly Phase IV, not Phase III/IIIb or Phase II/III. The primary endpoint is also a quality-of-life deterioration, not a standard oncology efficacy endpoint like OS or PFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group. PMID 37199022 · Pediatr Blood Cancer · 2023-Aug 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2. PMID 37191738 · Rheumatol Ther · 2023-Aug The study is not oncology-related; it evaluates a drug (upadacitinib) in non-radiographic axial spondyloarthritis. The primary analysis is a quality-of-life and work productivity assessment, not a time-to-event efficacy endpoint like OS, PFS, or DFS. Therefore, it does not meet the inclusion criteria. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. PMID 37182801 · Ann Oncol · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours. PMID 37179439 · Br J Cancer · 2023-Aug 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance). PMID 37179438 · Br J Cancer · 2023-Aug This is a secondary observational/lifestyle analysis (sleep duration) nested within a randomized adjuvant chemotherapy trial (CALGB/SWOG 80702). While it reports time-to-event efficacy endpoints (DFS, OS) with hazard ratios from the trial population, it is not the original formal-result report of the primary randomized trial's efficacy evaluation. The trial phase is not explicitly stated in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2). PMID 37170037 · Ann Surg Oncol · 2023-Aug 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
L
B
|
旧查询独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized controlled study of pain education in patients receiving radiotherapy for painful bone metastases. PMID 37169300 · Radiother Oncol · 2023-Aug The study is an oncology randomized trial with a primary time-to-event efficacy endpoint (time to pain control, reported with median times and p-value). However, it is not eligible because it lacks a drug-containing intervention; the intervention is a nurse-led pain education program, which is a non-drug intervention. The phase is not specified, but even if it were Phase III, the absence of a drug intervention excludes it. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| To cut or not to cut? A prospective randomized controlled trial on short-term outcomes of the uncut Roux-en-Y reconstruction for gastric cancer. PMID 37160808 · Surg Endosc · 2023-Aug 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |